Immunicom is a startup based in the United States, 1 tracked investor.
Based in the United States, Immunicom is a startup. Brouky records 1 investor associated with the company.
Immunicom develops novel immunotherapies, including its Immunopheresis® technology, designed to improve cancer treatment by enhancing patients' immune response while reducing typical side effects.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.